.Attribute Medicine, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of clients along with HER2+ sophisticated bosom cancer and energetic or dependable mind metastases revealed constant intracranial task and also systemic efficacy of T-DXd.